Glioblastoma in the real-world setting: patterns of care and outcome in the Austrian population

被引:1
作者
Hainfellner, Andreas [1 ,2 ]
Borkovec, Martin [1 ]
Seebrecht, Lukas [1 ]
Neuhauser, Magdalena [1 ]
Roetzer-Pejrimovsky, Thomas [1 ]
Greutter, Lisa [1 ,3 ]
Surboeck, Birgit [4 ]
Hager-Seifert, Andrea [5 ]
Gorka-vom Hof, Doris [6 ]
Urbanic-Purkart, Tadeja [6 ]
Stultschnig, Martin [7 ]
Cijan, Clemens [7 ]
Wuertz, Franz [8 ]
Calabek-Wohinz, Bernadette [9 ]
Pichler, Josef [10 ]
Hoellmueller, Isolde [10 ]
Leibetseder, Annette [11 ]
Weis, Serge [12 ,13 ]
Kleindienst, Waltraud [14 ]
Seiberl, Michael [14 ]
Bieler, Lara [14 ]
Hecker, Constantin [14 ,15 ]
Schwartz, Christoph [15 ]
Iglseder, Sarah [16 ]
Heugenhauser, Johanna [16 ]
Nowosielski, Martha [16 ]
Thome, Claudius [17 ]
Moser, Patrizia [18 ]
Hoffermann, Markus [19 ]
Loibnegger, Karin [20 ]
Dieckmann, Karin [21 ]
Tomschik, Matthias [22 ]
Widhalm, Georg [22 ]
Roessler, Karl [22 ]
Marosi, Christine [23 ,24 ]
Woehrer, Adelheid [1 ]
Hainfellner, Johannes A. [1 ]
Oberndorfer, Stefan [9 ,25 ]
机构
[1] Med Univ Vienna, Comprehens Ctr Clin Neurosci & Mental Hlth, Dept Neurol,Div Neuropathol & Neurochem, Med Univ Campus AKH 4J,Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Ctr Anat & Cell Biol, Div Anat, Vienna, Austria
[3] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria
[4] Clin Favoriten, Dept Neurol, Vienna, Austria
[5] State Hosp Wr Neustadt, Dept Neurol, Wr Neustadt, Austria
[6] Med Univ Graz, Dept Neurol, Graz, Austria
[7] State Hosp Klagenfurt, Dept Pathol, Klagenfurt, Austria
[8] State Hosp Klagenfurt, Dept Pathol, Klagenfurt, Austria
[9] Univ Hosp St Polten, Dept Neurol, Dunant Pl 1, A-3100 St Polten, Austria
[10] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Internal Med & Neurooncol, Neuromed Campus, Linz, Austria
[11] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Neurol 1, Neuromed Campus, Linz, Austria
[12] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Pathol & Mol Pathol, Div Neuropathol, Neuromed Campus, Linz, Austria
[13] Johannes Kepler Univ Linz, Clin Res Inst Neurosci, Linz, Austria
[14] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Neurol, Salzburg, Austria
[15] Paracelsus Med Univ Salzburg, Univ Hosp Salzburg, Dept Neurosurg, Salzburg, Austria
[16] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[17] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria
[18] Tirol Kliniken GmbH, Lab Neuropathol, Innsbruck, Austria
[19] State Hosp Feldkirch, Dept Paediat, Feldkirch, Austria
[20] State Hosp Feldkirch, Dept Radiat Oncol, Feldkirch, Austria
[21] Med Univ Vienna, Comprehens Canc Ctr, Dept Radiat Oncol, Vienna, Austria
[22] Med Univ Vienna, Comprehens Ctr Clin Neurosci & Mental Hlth, Dept Neurosurg, Vienna, Austria
[23] Med Univ Vienna, Div Palliat Care, Dept Internal Med 1, Comprehens Canc Ctr, Vienna, Austria
[24] Med Univ Vienna, Dept Internal Med 1, Div Oncol, Vienna, Austria
[25] Univ Hosp St Polten, Karl Landsteiner Inst Clin Neurol & Neuropsychol, Dept Neurol, St Polten, Austria
关键词
Glioblastoma; Prognosis; Outcome; Registry; NEWLY-DIAGNOSED GLIOBLASTOMA; BRAIN-TUMOR REGISTRY; 5-AMINOLEVULINIC ACID; TEMOZOLOMIDE THERAPY; PROGNOSTIC-FACTORS; SURVIVAL; RADIOTHERAPY; RESECTION; ASSOCIATION; EXTENT;
D O I
10.1007/s11060-024-04808-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose We present results of a retrospective population-based investigation of patterns of care and outcome of glioblastoma patients in Austria. Patients and methods In this nation-wide cooperative project, all Austrian glioblastoma patients newly diagnosed between 2014 and 2018 and registered in the ABTR-SANOnet database were included. Histological typing used criteria of the WHO classification of CNS tumors, 4th edition 2016. Patterns of care were assessed, and all patients were followed until the end of 2019. Results 1,420 adult glioblastoma cases were identified. 813 (57.3%) patients were male and 607 (42.7%) female. Median age at diagnosis was 64 years (range: 18-88). Median overall survival (OS) was 11.6 months in the total cohort and 10.9 months in patients with proven IDH-wildtype. Median OS in the patient group <= 65 years receiving postoperative standard of care therapy was 16.1 months. In the patient group > 65 years with postoperative therapy, median OS was 11.2 months. Follow-up >= 5 years identified 13/264 (4.9%) long-term survivors. Brain tumor surgery frequently was assisted by 5-aminolevulinic acid (5-ALA) fluorescence (up to 55%). Postoperative treatment was initiated around one month after surgery (median: 31 days) following standardized protocols in 1,041/1,420 (73.3%) cases. In 830 patients (58.5%), concomitant radiochemotherapy was started according to the established standard of care. Treatment in case of progressive disease was considerably variable. 170/1,420 patients (12.0%) underwent a second surgical procedure, 467 (33.0%) received systemic treatment after progression, and 173 (12.2%) were re-irradiated. Conclusion Our data illustrate and confirm nation-wide translation of effective standard of care to Austrian glioblastoma patients in the recent past. In the case of progressive disease, highly variable therapeutic approaches were used, most frequently accompanied by anti-angiogenic therapy. Long-term survival was observed in a minor proportion of mostly younger patients who typically had gross total tumor resection, a favorable postoperative ECOG score, and standard of care therapy.
引用
收藏
页码:407 / 418
页数:12
相关论文
共 37 条
  • [1] [Anonymous], 2021, World Health Organization Classification of Tumours of the Central Nervous System
  • [2] Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis
    Ballo, Matthew T. T.
    Conlon, Patrick
    Lavy-Shahaf, Gitit
    Kinzel, Adrian
    Vymazal, Josef
    Rulseh, Aaron M. M.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2023, 164 (1) : 1 - 9
  • [3] French brain tumor data bank:: Methodology and first results on 10,000 cases
    Bauchet, Luc
    Rigau, Valerie
    Mathieu-Daude, Helene
    Figarella-Branger, Dominique
    Hugues, Delphine
    Palusseau, Loreleie R.
    Bauchet, Fabienne
    Fabbro, Michel
    Campello, Chantal
    Capelle, Laurent
    Durand, Anne
    Tretarre, Brigitte
    Frappaz, Didier
    Henin, Dominique
    Menei, Philippe
    Honnorat, Jerome
    Segnarbieux, Francois
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2007, 84 (02) : 189 - 199
  • [4] Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions
    Bienkowski, Michal
    Berghoff, Anna S.
    Marosi, Christine
    Woehrer, Adelheid
    Heinzl, Harald
    Hainfellner, Johannes A.
    Preusser, Matthias
    [J]. CLINICAL NEUROPATHOLOGY, 2015, 34 (05) : 250 - 257
  • [5] Association of the Extent of Resection With Survival in Glioblastoma A Systematic Review and Meta-analysis
    Brown, Timothy J.
    Brennan, Matthew C.
    Li, Michael
    Church, Ephraim W.
    Brandmeir, Nicholas J.
    Rakszawski, Kevin L.
    Patel, Akshal S.
    Rizk, Elias B.
    Suki, Dima
    Sawaya, Raymond
    Glantz, Michael
    [J]. JAMA ONCOLOGY, 2016, 2 (11) : 1460 - 1469
  • [6] Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015
    Davis, Faith G.
    Smith, Trenton R.
    Gittleman, Haley R.
    Ostrom, Quinn T.
    Kruchko, Carol
    Barnholtz-Sloan, Jill S.
    [J]. NEURO-ONCOLOGY, 2020, 22 (02) : 301 - 302
  • [7] Patterns and disparities of care in glioblastoma
    Dressler, Emily V.
    Liu, Meng
    Garcia, Catherine R.
    Dolecek, Therese A.
    Pittman, Thomas
    Huang, Bin
    Villano, John L.
    [J]. NEURO-ONCOLOGY PRACTICE, 2019, 6 (01) : 37 - 46
  • [8] Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study
    Fabbro-Peray, Pascale
    Zouaoui, Sonia
    Darlix, Amelie
    Fabbro, Michel
    Pallud, Johan
    Rigau, Valerie
    Mathieu-Daude, Helene
    Bessaoud, Faiza
    Bauchet, Fabienne
    Riondel, Adeline
    Sorbets, Elodie
    Charissoux, Marie
    Amelot, Aymeric
    Mandonnet, Emmanuel
    Figarella-Branger, Dominique
    Duffau, Hugues
    Tretarre, Brigitte
    Taillandier, Luc
    Bauchet, Luc
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2019, 142 (01) : 91 - 101
  • [9] New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
    Gorlia, Thierry
    Stupp, Roger
    Brandes, Alba A.
    Rampling, Roy R.
    Fumoleau, Pierre
    Dittrich, Christian
    Campone, Mario M.
    Twelves, Chris C.
    Raymond, Eric
    Hegi, Monika E.
    Lacombe, Denis
    van den Bent, Martin J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (08) : 1176 - 1184
  • [10] Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009
    Gramatzki, Dorothee
    Dehler, Silvia
    Rushing, Elisabeth Jane
    Zaugg, Kathrin
    Hofer, Silvia
    Yonekawa, Yasuhiro
    Bertalanffy, Helmut
    Valavanis, Anton
    Korol, Dimitri
    Rohrmann, Sabine
    Pless, Miklos
    Oberle, Joachim
    Roth, Patrick
    Ohgaki, Hiroko
    Weller, Michael
    [J]. CANCER, 2016, 122 (14) : 2206 - 2215